Semaglutide Started at Hospital Discharge After Heart Attack: Real-World Study | Research

The takeaway

Early real-world use of semaglutide prescribed at hospital discharge after acute coronary syndrome appears feasible in type 2 diabetes patients.

Discharge-initiated semaglutide
First real-world data on starting GLP-1 therapy immediately after acute coronary syndrome

What the researchers found

Semaglutide prescribed at hospital discharge after acute coronary syndrome in T2DM patients was feasible in real-world practice, providing exploratory data on early post-ACS GLP-1 RA initiation.

Why it matters

Starting cardiovascular-protective medications early after a heart attack could maximize benefit during the highest-risk period for recurrent events.

How the study worked

Retrospective, multicenter observational study of adults with T2DM hospitalized for ACS who were prescribed semaglutide at discharge.

What this study cannot tell us

Retrospective observational design. Exploratory study — no control group or randomization. Small study with limited follow-up likely.

How to read the evidence

Retrospective observational study — exploratory evidence for a novel prescribing strategy, not definitive.

When this study was published

Published in 2026; addresses a gap in post-ACS medication management.

The bigger picture

This reflects a clinical trend toward earlier initiation of cardioprotective GLP-1 drugs, potentially extending their benefits to the acute phase of cardiovascular disease.

Questions still open

Should semaglutide become part of standard post-heart-attack medication protocols?
Does early post-ACS semaglutide initiation reduce 30-day readmission rates?

Common questions

Can I start semaglutide after a heart attack?

This study suggests it is feasible to start semaglutide at hospital discharge after a heart attack for diabetes patients. Always follow your cardiologist's recommendations for your specific situation.

Why start GLP-1 drugs early after a heart attack?

Semaglutide has proven cardiovascular benefits in diabetes patients. Starting it early after a heart attack could provide protection during the highest-risk period for repeat events.

Read the original research

Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.

Journal of cardiovascular medicine (Hagerstown, Md.), 27(2), 144-150

View on PubMed ↗Publisher’s paper ↗

Citation

Biasin, Marco; Stratinaki, Maria; Cordioli, Nicolò; Armani, Ilaria; De Giovanni, Sara; Aletras, George; Betta, Davide; Callegarin, Luca; Gambaro, Alessia; Morani, Giovanni. (2026). Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.. Journal of cardiovascular medicine (Hagerstown, Md.), 27(2), 144-150. https://doi.org/10.2459/JCM.0000000000001837